# SiNuo New Drugs

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sinuo-new-drugs

- Industry: Pharmaceuticals
- Headquarters: Nanjing, China
- Latest round: Series A (Mar 3, 2026)
- Investors on record: 1

## About

Founded in 2021 and based in Nanjing, China, Nanjing SiNuo New Drug R&D Co., Ltd., dba SiNuo New Drugs, focuses on the research and development of radiopharmaceuticals, aiming to build integrated diagnostic-to-therapeutic drug solutions. In March 2026, SiNuo New Drugs raised Series A+ funding from Star Capital.
SiNuo New Drugs specializes in radiopharmaceutical R&D, including targeted radioactive isotope-labeled drugs, supporting both diagnostic imaging and therapeutic applications, and provides integrated development from discovery to preclinical stages.
The company’s revenue is generated from out-licensing of radiopharmaceutical drug candidates, collaborative R&D and co-development partnerships, and milestone-based payments related to diagnostic and therapeutic nuclear medicine programs.

## Funding rounds

- Series A, Mar 3, 2026 — Star Capital

## Investors

- Star Capital — Series A